Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Intellia Therapeutics (NTLA) over the last 5 years, with Dec 2024 value amounting to -$5.25.

  • Intellia Therapeutics' EPS (Weighted Average and Diluted) rose 31.34% to -$0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.26, marking a year-over-year increase of 21.69%. This contributed to the annual value of -$5.25 for FY2024, which is 3.14% up from last year.
  • Intellia Therapeutics' EPS (Weighted Average and Diluted) amounted to -$5.25 in FY2024, which was up 3.14% from -$5.42 recorded in FY2023.
  • Intellia Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$2.40 during FY2020, with a 5-year trough of -$6.16 in FY2022.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$5.61, with a median of -$5.42 in 2023.
  • As far as peak fluctuations go, Intellia Therapeutics' EPS (Weighted Average and Diluted) tumbled by 62.96% in 2022, and later grew by 12.01% in 2023.
  • Intellia Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.40 in 2020, then slumped by 57.50% to -$3.78 in 2021, then tumbled by 62.96% to -$6.16 in 2022, then grew by 12.01% to -$5.42 in 2023, then increased by 3.14% to -$5.25 in 2024.